Developer docs
API playgroundTry for free, no card

Search company profiles

The Aurum Institute

Full company profile

uuid000anut

Namestring
The Aurum Institute
Legal namestring
The Aurum Institute
Company typeenum
Private
Founded yearint
2000
Descriptiontext

The Aurum Institute is a South Africa-based non-profit health impact organization founded circa 2000 and headquartered in Johannesburg, with 1,001–5,000 employees and operations spanning 78 countries. Its core offering is organized into three service divisions: Clinical Research (basic science, multi-site clinical trials for drugs, vaccines, and regimens, supported by biorepository and clinical laboratory capabilities); Implementation Research (epidemiology and geomapping, real-world evidence generation, and multi-site implementation studies); and Health Programmes (major development interventions, targeted projects, technical assistance, and infrastructure development). Therapeutic areas include Tuberculosis, HIV, COVID-19, Health Systems Strengthening, Market Access, and Antimicrobial Resistance, with impact metrics of 1.5 million people screened for TB, over 15 million tested for HIV, 412,702 COVID vaccines administered, and more than 13 million patient courses of rifapentine-based TB preventive treatments delivered across 78 countries.

The organization is funded primarily through grants and partnerships rather than commercial sales. Unitaid's US$52 million SUPREME initiative (March 2026), with CHAI and Amref, addresses maternal health across seven African countries, while IMPAACT4TB was a Unitaid-funded TB project managed by Aurum through its 2025 close-out. Geographic reach extends through country entities in Ghana, Mozambique, the USA (Aurum USA), and Brazil (Fundação Aurum), with affiliate brands IMPAACT4TB, INNOVA, Youth Health Africa, and GHI. Founder and CEO Gavin Churchyard leads the organization under a Board of Directors and Group Executive Management governance structure. Recent risk signals include referenced cuts to US government research grants affecting Aurum and peer organizations in the National BioData Consortium context.

The business model is non-commercial: Aurum does not sell products or APIs, operates no software platform, and does not disclose pricing. Revenue derives from restricted and unrestricted grants, donor funding, and institutional partnerships. Customer-facing work is delivered through governments, public health programmes, and international health organizations, positioning Aurum as an implementation and evidence-generation intermediary between global health funders and on-the-ground public health delivery in Africa.

Short descriptiontext

The Aurum Institute is a South Africa-based non-profit health research and implementation organization founded circa 2000, delivering clinical trials, implementation research, and health programmes across 78 countries, primarily focused on tuberculosis, HIV, COVID-19, and health system strengthening in Africa.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersJohannesburg, South Africa
HQ citystring
Johannesburg
HQ countrystring
South Africa
HQ regionstring
Africa
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical research services, global health programmes, tuberculosis prevention, HIV testing treatment, health systems strengthening
Industry4 codes
PRIMARYHLAJAKAN
Global Health Research, Evidence & Technical Assistance Organizations
Healthcare & Life Sciences/Public Health, Government & Regulators/Global Health & Development Agencies (NGOs/Multilaterals)
SECONDARYHLAKAGAH
Tuberculosis & Mycobacterial Diseases
SECONDARYEDAHAGAM
Global Health Institutes & Programs
Education/Higher Education (Colleges & Universities)/Medical & Health Sciences Universities
SECONDARYHLAJAOAE
Disease-Specific Global Initiatives (HIV/TB/Malaria/NTDs)
NAICS code2 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
Product category
Global Public Health Research and Implementation Services
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Others
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1IMPAACT4TB
Description

A project focused on TB research and implementation for children and adolescents

auruminstitute.org
+2 more records
Core offering1 text field

The Aurum Institute is a nonprofit health impact organisation that conducts clinical and implementation research and delivers large-scale health programmes focused on tuberculosis, HIV, COVID-19, antimicrobial resistance, and health systems strengthening. It operates clinical research facilities including biorepositories and laboratories, runs multi-site clinical trials for drugs, vaccines, and regimens, and executes major development intervention programmes with technical assistance to governments across Africa and globally.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 1.5 million people screened for TB
+3 more records
Product overview1 text field

The Aurum Institute is a health impact organization operating as a single unified offering rather than a platform-plus-modules architecture. Its core services consist of three interconnected divisions: Clinical Research (providing basic science, multi-site clinical trials, biorepository, and clinical laboratory services), Implementation Research (delivering epidemiology, geomapping, real-world evidence, and multi-site implementation studies), and Health Programmes (executing development interventions, targeted projects, technical assistance, and infrastructure development). These services are organized around therapeutic areas including Tuberculosis, HIV, COVID-19, Health Systems, Market Access, and Antimicrobial Resistance. The organization maintains global reach through affiliates IMPAACT4TB, INNOVA, and Youth Health Africa, with international operations in Ghana, Mozambique, USA, and Brazil through Fundação Aurum. Aurum is NOT a technology product company—it does not offer software products, APIs, AI-powered tools, or integrations.

Product and service12 records
1Clinical Research Division
CategoryClinical Research Services
Description

Provides basic science research, multi-site clinical trials for drugs, vaccines and regimens, biorepository, and clinical laboratory services for governments, donors, and research partners.

2Implementation Research Division
CategoryImplementation Research Services
Description

Conducts epidemiology and geomapping, real-world evidence generation, and multi-site implementation studies for public health programmes and policy makers.

3Health Programmes
CategoryHealth Programme Implementation
Description

Delivers major development intervention programmes, targeted intervention projects, technical assistance, and infrastructure development for governments and donor-funded health initiatives.

4Tuberculosis Prevention & Treatment Programme
CategoryTherapeutic Area Programme - Tuberculosis
Description

Comprehensive TB screening, testing, and rifapentine-based preventive treatment programme that has reached over 13 million patient courses across 78 countries.

5HIV Prevention & Treatment Programme
CategoryTherapeutic Area Programme - HIV
Description

HIV testing and treatment services integrated with TB programmes, with over 15 million people tested to date across Africa.

6COVID-19 Response Programme
CategoryTherapeutic Area Programme - COVID-19
Description

COVID-19 vaccination and pandemic response programme, including the administration of 412,702 COVID-19 vaccines to date.

7Antimicrobial Resistance (AMR) Programme
CategoryTherapeutic Area Programme - Antimicrobial Resistance
Description

Programme addressing antimicrobial resistance challenges through research and implementation activities.

8Health Systems Strengthening
CategoryService Area - Health Systems Strengthening
Description

Service area covering quality improvement, system improvement, health information systems, and market shaping initiatives for government and donor partners.

9Market Access
CategoryService Area - Market Access
Description

Programmes focused on improving access to health products and treatments across African and other low- and middle-income markets.

10IMPAACT4TB
CategoryAffiliate Programme - Tuberculosis
Description

Unitaid-funded project managed by Aurum focused on TB prevention and treatment, particularly for children and adolescents.

11INNOVA
CategoryAffiliate Programme - Health Innovation
Description

Affiliate organisation of The Aurum Institute focused on health innovation and technology initiatives.

12Youth Health Africa
CategoryAffiliate Programme - Youth Health
Description

Affiliate organisation of The Aurum Institute delivering youth-focused health programmes and employment initiatives in Africa.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1CHAI (Clinton Health Access Initiative)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborates with Aurum on the SUPREME initiative alongside Unitaid and Amref to tackle preeclampsia and anemia across seven African countries.

auruminstitute.org
2Amref
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partners with Aurum on the SUPREME initiative to provide expertise alongside CHAI and Unitaid funding to address preeclampsia and anemia across seven African countries.

auruminstitute.org
3IMPAACT4TB
Strategic tierCoreTypeStrategic or Co-development Partner
Description

A Unitaid-funded project managed by Aurum that marked its global close-out at the Union World Conference on Lung Health 2025. The project worked on TB treatment and prevention.

auruminstitute.org
4Youth Health Africa
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Affiliate organization focused on youth health initiatives in Africa.

auruminstitute.org
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Affiliate organization of The Aurum Institute focused on health innovation.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Affiliate organization operating in South Africa.

7National BioData Consortium (NBDC)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration referenced in blockchain for genetic data sharing context. Organizations like Aurum and NBDC have faced severe cuts to US government research grants.

auruminstitute.org
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global nonprofit that pairs clinical research with health system strengthening and direct care delivery in low-resource settings. Closely comparable to Aurum's integrated research-plus-implementation model, particularly across HIV, TB, and maternal health in Africa and the Caribbean.

TypeDirect peer
Description

Dutch-based TB-focused NGO with deep experience in TB prevention, treatment, and policy advocacy in low- and middle-income countries. Directly comparable to Aurum's TB franchise, including rifapentine-based preventive therapy rollouts and technical assistance to national TB programmes.

TypeDirect peer
Description

Global health organization that works with governments to strengthen health systems and improve access to medicines for HIV, TB, malaria, and maternal health. Directly comparable as both a co-implementer on Aurum's SUPREME initiative and a peer in evidence-to-policy and market-shaping work.

TypeBroad incumbent
Description

Large international NGO combining implementation research, clinical trials, and health programme delivery across HIV, TB, and infectious disease in developing countries. Broader and more diversified than Aurum, but operates a similar research-to-implementation model with global reach.

5PATH
TypeBroad incumbent
Description

Global health innovation organization with significant work in vaccines, diagnostics, and infectious disease across low- and middle-income countries. Comparable to Aurum in its mix of clinical research, implementation, and market-shaping activities, though at substantially larger scale.

TypeDirect peer
Description

Uganda-based African clinical research and training institute with strong HIV and TB programmes, biorepository capacity, and implementation research expertise. Closely comparable to Aurum as a fellow African-headquartered research-to-implementation NGO.

TypeRegional player
Description

South African clinical research and health systems organization affiliated with the University of the Witwatersrand, with comparable HIV and TB trial and implementation activity. Functions as a domestic South African peer with overlapping funder base and disease focus.

TypeDirect peer
Description

Global nonprofit focused on HIV prevention, treatment, and research, with substantial footprint across sub-Saharan Africa. Directly comparable to Aurum on HIV testing/treatment scale (15M+ HIV tests) and on integration with maternal and child health programming.

TypeEmerging player
Description

Product Development Partnership developing and delivering improved TB regimens, including work on rifapentine-based preventive therapy that overlaps with Aurum's IMPAACT4TB franchise. Comparable as a TB-focused R&D and access organization, though more product-development oriented than Aurum.

TypeEmerging player
Description

International nonprofit funding HIV/AIDS research and advocacy globally. Comparable to Aurum on the HIV research and policy translation dimension, though Aurum has a stronger implementation footprint than amfAR's primarily grant-making model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

The Aurum Institute

Global Public Health Research and Implementation Servicesauruminstitute.org

The Aurum Institute is a South Africa-based non-profit health research and implementation organization founded circa 2000, delivering clinical trials, implementation research, and health programmes across 78 countries, primarily focused on tuberculosis, HIV, COVID-19, and health system strengthening in Africa.

What The Aurum Institute does

The Aurum Institute is a South Africa-based non-profit health impact organization founded circa 2000 and headquartered in Johannesburg, with 1,001–5,000 employees and operations spanning 78 countries. Its core offering is organized into three service divisions: Clinical Research (basic science, multi-site clinical trials for drugs, vaccines, and regimens, supported by biorepository and clinical laboratory capabilities); Implementation Research (epidemiology and geomapping, real-world evidence generation, and multi-site implementation studies); and Health Programmes (major development interventions, targeted projects, technical assistance, and infrastructure development). Therapeutic areas include Tuberculosis, HIV, COVID-19, Health Systems Strengthening, Market Access, and Antimicrobial Resistance, with impact metrics of 1.5 million people screened for TB, over 15 million tested for HIV, 412,702 COVID vaccines administered, and more than 13 million patient courses of rifapentine-based TB preventive treatments delivered across 78 countries.

The organization is funded primarily through grants and partnerships rather than commercial sales. Unitaid's US$52 million SUPREME initiative (March 2026), with CHAI and Amref, addresses maternal health across seven African countries, while IMPAACT4TB was a Unitaid-funded TB project managed by Aurum through its 2025 close-out. Geographic reach extends through country entities in Ghana, Mozambique, the USA (Aurum USA), and Brazil (Fundação Aurum), with affiliate brands IMPAACT4TB, INNOVA, Youth Health Africa, and GHI. Founder and CEO Gavin Churchyard leads the organization under a Board of Directors and Group Executive Management governance structure. Recent risk signals include referenced cuts to US government research grants affecting Aurum and peer organizations in the National BioData Consortium context.

The business model is non-commercial: Aurum does not sell products or APIs, operates no software platform, and does not disclose pricing. Revenue derives from restricted and unrestricted grants, donor funding, and institutional partnerships. Customer-facing work is delivered through governments, public health programmes, and international health organizations, positioning Aurum as an implementation and evidence-generation intermediary between global health funders and on-the-ground public health delivery in Africa.

The Aurum Institute firmographics

Firmographics
Name
The Aurum Institute
Legal name
The Aurum Institute
Website
https://auruminstitute.org
Company type
Private
Founded year
2000
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
The Aurum Institute is a South Africa-based non-profit health research and implementation organization founded circa 2000, delivering clinical trials, implementation research, and health programmes across 78 countries, primarily focused on tuberculosis, HIV, COVID-19, and health system strengthening in Africa.
Ownership category
akta.pro rank

The Aurum Institute industry classification

Industry
Product category
Global Public Health Research and Implementation Services
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAJAKAN
Global Health Research, Evidence & Technical Assistance Organizations
Healthcare & Life Sciences/Public Health, Government & Regulators/Global Health & Development Agencies (NGOs/Multilaterals)
SECONDARYHLAKAGAH
Tuberculosis & Mycobacterial Diseases
SECONDARYEDAHAGAM
Global Health Institutes & Programs
Education/Higher Education (Colleges & Universities)/Medical & Health Sciences Universities
SECONDARYHLAJAOAE
Disease-Specific Global Initiatives (HIV/TB/Malaria/NTDs)

Keywords

  • Clinical research services
  • Global health programmes
  • Tuberculosis prevention
  • HIV testing treatment
  • Health systems strengthening

Where The Aurum Institute is headquartered

Location

Headquarters

HQ city
Johannesburg
HQ country
South Africa
HQ region
Africa

Offices1 record

Markets served

The Aurum Institute business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Others

Marketing channels2 records

The Aurum Institute product offering

Product offering

Core offering

The Aurum Institute is a nonprofit health impact organisation that conducts clinical and implementation research and delivers large-scale health programmes focused on tuberculosis, HIV, COVID-19, antimicrobial resistance, and health systems strengthening. It operates clinical research facilities including biorepositories and laboratories, runs multi-site clinical trials for drugs, vaccines, and regimens, and executes major development intervention programmes with technical assistance to governments across Africa and globally.

Product overview

The Aurum Institute is a health impact organization operating as a single unified offering rather than a platform-plus-modules architecture. Its core services consist of three interconnected divisions: Clinical Research (providing basic science, multi-site clinical trials, biorepository, and clinical laboratory services), Implementation Research (delivering epidemiology, geomapping, real-world evidence, and multi-site implementation studies), and Health Programmes (executing development interventions, targeted projects, technical assistance, and infrastructure development). These services are organized around therapeutic areas including Tuberculosis, HIV, COVID-19, Health Systems, Market Access, and Antimicrobial Resistance. The organization maintains global reach through affiliates IMPAACT4TB, INNOVA, and Youth Health Africa, with international operations in Ghana, Mozambique, USA, and Brazil through Fundação Aurum. Aurum is NOT a technology product company—it does not offer software products, APIs, AI-powered tools, or integrations.

Differentiator

Problem solved

Functional benefit

Brands

  • IMPAACT4TB: A project focused on TB research and implementation for children and adolescents
  • INNOVA
  • Youth Health Africa

Products and services

  • Clinical Research Division Provides basic science research, multi-site clinical trials for drugs, vaccines and regimens, biorepository, and clinical laboratory services for governments, donors, and research partners.
  • Implementation Research Division Conducts epidemiology and geomapping, real-world evidence generation, and multi-site implementation studies for public health programmes and policy makers.
  • Health Programmes Delivers major development intervention programmes, targeted intervention projects, technical assistance, and infrastructure development for governments and donor-funded health initiatives.
  • Tuberculosis Prevention & Treatment Programme Comprehensive TB screening, testing, and rifapentine-based preventive treatment programme that has reached over 13 million patient courses across 78 countries.
  • HIV Prevention & Treatment Programme HIV testing and treatment services integrated with TB programmes, with over 15 million people tested to date across Africa.
  • COVID-19 Response Programme COVID-19 vaccination and pandemic response programme, including the administration of 412,702 COVID-19 vaccines to date.
  • Antimicrobial Resistance (AMR) Programme Programme addressing antimicrobial resistance challenges through research and implementation activities.
  • Health Systems Strengthening Service area covering quality improvement, system improvement, health information systems, and market shaping initiatives for government and donor partners.
  • Market Access Programmes focused on improving access to health products and treatments across African and other low- and middle-income markets.
  • IMPAACT4TB Unitaid-funded project managed by Aurum focused on TB prevention and treatment, particularly for children and adolescents.
  • INNOVA Affiliate organisation of The Aurum Institute focused on health innovation and technology initiatives.
  • Youth Health Africa Affiliate organisation of The Aurum Institute delivering youth-focused health programmes and employment initiatives in Africa.

Quantifiable outcome

  • 1.5 million people screened for TB
  • +3 more outcomes

Companies that use The Aurum Institute

Customer profile

Segments1 record

Ideal customer profiles2 records

The Aurum Institute technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

The Aurum Institute partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • CHAI (Clinton Health Access Initiative)coreStrategic or Co-development PartnerCollaborates with Aurum on the SUPREME initiative alongside Unitaid and Amref to tackle preeclampsia and anemia across seven African countries.
  • AmrefcoreStrategic or Co-development PartnerPartners with Aurum on the SUPREME initiative to provide expertise alongside CHAI and Unitaid funding to address preeclampsia and anemia across seven African countries.
  • IMPAACT4TBcoreStrategic or Co-development PartnerA Unitaid-funded project managed by Aurum that marked its global close-out at the Union World Conference on Lung Health 2025. The project worked on TB treatment and prevention.
  • Youth Health AfricaminorStrategic or Co-development PartnerAffiliate organization focused on youth health initiatives in Africa.
  • INNOVAminorStrategic or Co-development PartnerAffiliate organization of The Aurum Institute focused on health innovation.
  • GHI (Global Health Impact)minorStrategic or Co-development PartnerAffiliate organization operating in South Africa.
  • National BioData Consortium (NBDC)minorStrategic or Co-development PartnerCollaboration referenced in blockchain for genetic data sharing context. Organizations like Aurum and NBDC have faced severe cuts to US government research grants.

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

The Aurum Institute competitors and assessment

Company assessment

Direct peers

  • Partners in Health: Global nonprofit that pairs clinical research with health system strengthening and direct care delivery in low-resource settings. Closely comparable to Aurum's integrated research-plus-implementation model, particularly across HIV, TB, and maternal health in Africa and the Caribbean.
  • KNCV Tuberculosis Foundation: Dutch-based TB-focused NGO with deep experience in TB prevention, treatment, and policy advocacy in low- and middle-income countries. Directly comparable to Aurum's TB franchise, including rifapentine-based preventive therapy rollouts and technical assistance to national TB programmes.
  • Clinton Health Access Initiative (CHAI): Global health organization that works with governments to strengthen health systems and improve access to medicines for HIV, TB, malaria, and maternal health. Directly comparable as both a co-implementer on Aurum's SUPREME initiative and a peer in evidence-to-policy and market-shaping work.
  • Infectious Diseases Institute (IDI): Uganda-based African clinical research and training institute with strong HIV and TB programmes, biorepository capacity, and implementation research expertise. Closely comparable to Aurum as a fellow African-headquartered research-to-implementation NGO.
  • Elizabeth Glaser Pediatric AIDS Foundation (EGPAF): Global nonprofit focused on HIV prevention, treatment, and research, with substantial footprint across sub-Saharan Africa. Directly comparable to Aurum on HIV testing/treatment scale (15M+ HIV tests) and on integration with maternal and child health programming.

Broad incumbents

  • FHI 360: Large international NGO combining implementation research, clinical trials, and health programme delivery across HIV, TB, and infectious disease in developing countries. Broader and more diversified than Aurum, but operates a similar research-to-implementation model with global reach.
  • PATH: Global health innovation organization with significant work in vaccines, diagnostics, and infectious disease across low- and middle-income countries. Comparable to Aurum in its mix of clinical research, implementation, and market-shaping activities, though at substantially larger scale.

Regional players

  • Wits Health Consortium: South African clinical research and health systems organization affiliated with the University of the Witwatersrand, with comparable HIV and TB trial and implementation activity. Functions as a domestic South African peer with overlapping funder base and disease focus.

Emerging players

  • TB Alliance: Product Development Partnership developing and delivering improved TB regimens, including work on rifapentine-based preventive therapy that overlaps with Aurum's IMPAACT4TB franchise. Comparable as a TB-focused R&D and access organization, though more product-development oriented than Aurum.
  • amfAR, The Foundation for AIDS Research: International nonprofit funding HIV/AIDS research and advocacy globally. Comparable to Aurum on the HIV research and policy translation dimension, though Aurum has a stronger implementation footprint than amfAR's primarily grant-making model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

The Aurum Institute social profiles

Digital presence

The Aurum Institute compliance and trust

Trust signal

Compliance3 records

The Aurum Institute financial estimates

Financial estimate

Revenue estimate

Valuation estimate

The Aurum Institute leadership team

Management profile

Number of profiles

Profiles1 record

The Aurum Institute subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

The Aurum Institute funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

The Aurum Institute M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Aurum Institute

What does The Aurum Institute do?

The Aurum Institute is a nonprofit health impact organisation that conducts clinical and implementation research and delivers large-scale health programmes focused on tuberculosis, HIV, COVID-19, antimicrobial resistance, and health systems strengthening. It operates clinical research facilities including biorepositories and laboratories, runs multi-site clinical trials for drugs, vaccines, and regimens, and executes major development intervention programmes with technical assistance to governments across Africa and globally.

Is The Aurum Institute a public or private company?

The Aurum Institute is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was The Aurum Institute founded?

The Aurum Institute was founded in 2000. It employs 1,001 to 5,000 people.

Where is The Aurum Institute based?

The Aurum Institute is headquartered in Johannesburg, South Africa, in the Africa region.

Who are The Aurum Institute's main competitors?

Direct peers on record are Partners in Health, KNCV Tuberculosis Foundation, Clinton Health Access Initiative (CHAI), Infectious Diseases Institute (IDI) and Elizabeth Glaser Pediatric AIDS Foundation (EGPAF). Broad incumbents are FHI 360 and PATH. Wits Health Consortium is listed as a regional player. Emerging players are TB Alliance and amfAR, The Foundation for AIDS Research.

Does The Aurum Institute have an API?

No public API is recorded for The Aurum Institute.

What industry is The Aurum Institute in?

The Aurum Institute's product category is Global Public Health Research and Implementation Services. Its primary akta.pro industry code is HLAJAKAN, Global Health Research, Evidence & Technical Assistance Organizations, with a secondary code of HLAKAGAH, Tuberculosis & Mycobacterial Diseases. Its NAICS code is 621511 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GenomeWebRollout of 5,000 Near Point-of-Care TB Test Systems in 13 Countries Begins With $50M in FundingWith approximately $50 million in funding from the Children's Investment Fund Foundation, the Global Fund, and other public health organizations, an initial rollout of 5,000 PlusLife MiniDock Ultra instruments and 3 million tuberculosis tests has begun across 13 countries, coordinated by the Aurum Institute. The new near point-of-care TB diagnostic system, endorsed by the World Health Organization in March, can deliver results in 30 minutes using tongue swab samples at a cost of $3.60 per test and $155 per instrument—substantially lower than legacy molecular testing platforms that cost $10,000 to $20,000 per instrument with $8 per test. The rollout aims to address TB diagnosis challenges exacerbated by COVID-19 pandemic disruptions and global aid cuts, with a full-scale expansion expected in the next Global Fund funding cycle (GC8) next year.EIN PresswireIndyGeneUS Bio Launches Africa’s First AI×Bio Factory™ Accelerating AI-Driven Drug Discovery and Gene TherapiesIndyGeneUS Bio launched Africa's first AI×Bio Factory in South Africa with The Aurum Institute and Oracle Cloud Infrastructure. The facility aims to generate over one million African clinico-genomic insights for drug discovery and precision medicine. A MoU with Nigeria's NBRDA was also signed for future collaboration.GenomeWebBlockchain Offers Transparency, Security for Sharing Genetic Data, but Is No PanaceaResearchers and companies are exploring blockchain technology as a tool to improve transparency, security, and participant control in genomic data sharing, with platforms such as PrecisionChain, De-Bi, and the Native BioData Consortium's b-IDS demonstrating feasibility for streamlining clinical trial recruitment, rare disease research, and Indigenous data sovereignty. The article highlights significant adoption barriers including computational overhead, cultural resistance among centralized biobanks, and a challenging funding environment, with organizations like the NBDC and Aurum Institute facing severe cuts to US government research grants. Multiple historical cases of genetic data misuse affecting Indigenous and marginalized populations underscore the urgency for ethical data reuse frameworks, though experts note that technology alone cannot drive the behavior change required.BBCCoronavirus: Top South African HIV scientist Gita Ramjee diesGita Ramjee, a South African HIV scientist, died from Covid-19-related complications. She was chief scientific officer at the Aurum Institute and dedicated her career to HIV prevention for women. Tributes from colleagues and officials highlighted her legacy and the loss to the global fight against HIV.